Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Lexaria Bioscience Corp.: Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference | 199 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / August 27, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that... ► Artikel lesen | |
14.08. | Lexaria completes patient dosing in GLP-1 study, final results expected Q4 | 2 | Investing.com | ||
LEXARIA BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
14.08. | Lexaria Bioscience stock rises after completion of GLP-1 study milestone | 2 | Investing.com | ||
14.08. | Lexaria Bioscience Corp.: Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone | 292 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / August 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce... ► Artikel lesen | |
06.08. | Lexaria Bioscience Corp.: GLP-1 "Arms Race" Broadens to Include Dozens of Companies | 314 | ACCESS Newswire | Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria")... ► Artikel lesen | |
29.07. | H.C. Wainwright senkt Kursziel für Lexaria Bioscience wegen Aktienverwässerung | 1 | Investing.com Deutsch | ||
29.07. | H.C. Wainwright lowers Lexaria Bioscience stock price target on share dilution | 2 | Investing.com | ||
28.07. | Lexaria Bioscience Corp.: Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study | 718 | ACCESS Newswire | DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1... ► Artikel lesen | |
23.07. | Lexaria's DehydraTECH reduces side effects in GLP-1 drugs | 4 | Investing.com | ||
23.07. | Lexaria Bioscience Corp.: Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry | 283 | ACCESS Newswire | The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention... ► Artikel lesen | |
14.07. | Lexaria Bioscience Corp. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
01.07. | Kursziel für Lexaria Bioscience von H.C. Wainwright auf 5 US-Dollar gesenkt | 2 | Investing.com Deutsch | ||
01.07. | Lexaria Bioscience stock price target lowered to $5 at H.C. Wainwright | 1 | Investing.com | ||
23.06. | Lexaria Bioscience expands patent portfolio to 50 with new additions | 5 | Investing.com | ||
23.06. | Lexaria Bioscience Corp.: Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide | 225 | ACCESS Newswire | New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the... ► Artikel lesen | |
12.06. | Lexaria Bioscience Corp. - 8-K, Current Report | 2 | SEC Filings | ||
11.06. | Lexaria Bioscience Corp.: Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule | 276 | ACCESS Newswire | Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events ("AEs") as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct human clinical studies... ► Artikel lesen | |
05.06. | Lexaria Bioscience Corp.: Lexaria Attending BIO International Convention | 264 | ACCESS Newswire | Biotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator... ► Artikel lesen | |
12.05. | Lexaria advances drug delivery tech with PharmaCO | 2 | Investing.com | ||
12.05. | Lexaria Bioscience Corp.: Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company | 884 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 46,410 | +0,11 % | DAX-Check LIVE: Commerzbank, Fresenius, Gerresheimer, Lufthansa, Nordex, RWE | Der deutsche Leitindex zeigte sich zum Wochenschluss mit einer positiven Tendenz. Zum Börsenstart notierte der DAX noch leicht im Minus und bewegte sich zunächst seitwärts. Am Nachmittag gelang dann... ► Artikel lesen | |
CARL ZEISS MEDITEC | 43,100 | -0,74 % | Zuspruch für Nvidia, Zweifel an Siemens Energy, auch HelloFresh wird kritisch beäugt und ein Comeback von Carl Zeiss Meditec scheint sich nicht abzuzeichnen | Die Worte der Analysten finden an den Märkten stets viel Beachtung. Schließlich machen die Experten den lieben langen Tag nichts anderes, als Unternehmenszahlen, Marktdynamiken und dergleichen mehr... ► Artikel lesen | |
DRAEGERWERK | 66,20 | -1,05 % | Draegerwerk AG & Co. KGaA: Dräger bestätigt Q2-Trends und starker Auftragseingang unterstützt Visibilität. HALTEN. | Dräger bestätigt die Ergebnisse für das 2. Quartal 2025 mit einem Umsatzanstieg von 1,8% (wb.) auf 780 Mio EUR und einem EBIT von 20 Mio EUR, was den Wegfall von Einmalerträgen aus dem Vorjahr widerspiegelt.... ► Artikel lesen | |
MEDTRONIC | 79,18 | -0,19 % | Medtronic: 'Shining Light Through the Fog': How AI Makes Every Pulse Count | Medtronic is using artificial intelligence to design more accurate technology for all from the early days of innovation NORTHAMPTON, MA / ACCESS Newswire / August 26, 2025 / When Keith Holloman saw... ► Artikel lesen | |
INTUITIVE SURGICAL | 403,60 | -0,25 % | What Does Wall Street Think About Intuitive Surgical (ISRG) Stock? | ||
GERRESHEIMER | 43,120 | +1,60 % | Gerresheimer mit EILMELDUNG: Könnte die Aktie am Montag komplett einbrechen - Experten warnen!!! | ||
TELADOC HEALTH | 6,636 | +0,48 % | Teladoc: A Telehealth Titan in Trouble? | ||
THERMO FISHER | 420,75 | -0,12 % | Should You Continue to Hold Thermo Fisher Stock in Your Portfolio? | ||
ROKU | 82,18 | -0,41 % | Cathie Wood's ARK shifts focus, buys Intellia stock, sells Roku and DraftKings | ||
HIMS & HERS HEALTH | 36,210 | +0,06 % | HIMS vs. AMWL: Which Stock Has the Stronger Global Growth Strategy? | ||
SERNOVA BIOTHERAPEUTICS | 0,115 | +6,48 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
DEXCOM | 64,59 | +0,28 % | If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today | ||
ALCON | 68,22 | 0,00 % | Aktien-Trading 4 Dummies - 3 Aktien. 2 Experten. 0 Langeweile (Apple, Canopy Growth & Alcon) | ||
RESMED | 232,80 | -0,72 % | Resmed, Inc.: Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds | Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized careSAN... ► Artikel lesen | |
HEALWELL AI | 0,808 | -0,62 % | HEALWELL gibt Rekordumsatzwachstum von 645 % im 2. Quartal 2025 bekannt und schließt erstmals Quartal mit positivem bereinigtem EBITDA ab | - HEALWELL erzielte im zweiten Quartal 2025 einen Umsatz aus fortlaufenden Betrieben in Höhe von 40,5 Millionen $ - um 645 % mehr als die 5,4 Millionen $ im zweiten Quartal
2024. Das... ► Artikel lesen |